IDEAYA Biosciences (NASDAQ:IDYA) Stock Gets Price Target Cut from JPMorgan Chase & Co.

IDEAYA Biosciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • JPMorgan cut its IDEAYA Biosciences price target from $62 to $55 but maintained an “overweight” rating; the new target implies 114.34% upside from the share price cited in the report.
  • Analyst sentiment remains broadly positive: MarketBeat reports a “Moderate Buy” consensus and a $50 average target, with 14 Buy, one Hold, and one Sell rating.
  • Shares fell 1.9% to $25.66 on Friday. In its latest quarter, IDEAYA missed EPS expectations ($-1.22 versus $-1.18) but revenue beat forecasts at $10.24 million and rose 14.6% year over year.
  • Five stocks we like better than IDEAYA Biosciences.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) had its price target lowered by equities researchers at JPMorgan Chase & Co. from $62.00 to $55.00 in a report issued on Friday, Benzinga reports. The firm currently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s target price would suggest a potential upside of 114.34% from the stock's current price.

A number of other research firms have also issued reports on IDYA. Wall Street Zen lowered shares of IDEAYA Biosciences from a "hold" rating to a "sell" rating in a report on Saturday, August 15th. Royal Bank Of Canada reiterated an "outperform" rating and set a $45.00 price target on shares of IDEAYA Biosciences in a report on Tuesday. Guggenheim reduced their price objective on shares of IDEAYA Biosciences from $57.00 to $52.00 and set a "buy" rating on the stock in a research note on Wednesday, November 4th. Wedbush raised their target price on shares of IDEAYA Biosciences from $60.00 to $63.00 and gave the stock an "outperform" rating in a research report on Wednesday, November 4th. Finally, Jefferies Financial Group reaffirmed a "buy" rating on shares of IDEAYA Biosciences in a research note on Tuesday, September 1st. Fourteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $50.00.

Read Our Latest Report on IDYA

IDEAYA Biosciences Trading Down 1.9%

Shares of IDYA traded down $0.51 during trading hours on Friday, reaching $25.66. The company had a trading volume of 453,683 shares, compared to its average volume of 1,033,991. The firm has a 50 day simple moving average of $34.59 and a 200-day simple moving average of $33.79. The company has a market capitalization of $2.48 billion, a price-to-earnings ratio of -5.71 and a beta of 0.08. IDEAYA Biosciences has a 12-month low of $25.71 and a 12-month high of $42.68.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported ($1.22) earnings per share for the quarter, missing analysts' consensus estimates of ($1.18) by ($0.04). The firm had revenue of $10.24 million during the quarter, compared to analysts' expectations of $7.58 million. IDEAYA Biosciences had a negative net margin of 1,157.18% and a negative return on equity of 39.78%. The company's quarterly revenue was up 14.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.33 EPS. Sell-side analysts forecast that IDEAYA Biosciences will post -4.68 earnings per share for the current year.

Insider Activity at IDEAYA Biosciences

In other news, CEO Yujiro Hata sold 26,338 shares of IDEAYA Biosciences stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $37.41, for a total value of $985,304.58. Following the transaction, the chief executive officer directly owned 690,695 shares of the company's stock, valued at $25,838,899.95. The trade was a 3.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 4.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Allworth Financial LP raised its stake in shares of IDEAYA Biosciences by 95.8% during the third quarter. Allworth Financial LP now owns 883 shares of the company's stock valued at $34,000 after purchasing an additional 432 shares during the period. Quantbot Technologies LP bought a new stake in IDEAYA Biosciences in the 2nd quarter valued at about $43,000. Sterling Capital Management LLC increased its stake in IDEAYA Biosciences by 20.5% during the 3rd quarter. Sterling Capital Management LLC now owns 1,873 shares of the company's stock valued at $72,000 after buying an additional 319 shares during the period. Nykredit A S acquired a new position in shares of IDEAYA Biosciences in the 2nd quarter worth approximately $76,000. Finally, GAMMA Investing LLC lifted its holdings in shares of IDEAYA Biosciences by 79.0% during the third quarter. GAMMA Investing LLC now owns 2,315 shares of the company's stock valued at $89,000 after purchasing an additional 1,022 shares during the last quarter. 98.29% of the stock is owned by hedge funds and other institutional investors.

About IDEAYA Biosciences

(Get Free Report)

IDEAYA Biosciences, Inc. is a precision oncology company focused on discovering and developing targeted medicines for patients with cancer. Its research uses insights into tumor genetics and synthetic lethality—the idea that certain genetic changes can make cancer cells especially vulnerable to blocking a related biological pathway—to identify potential treatment targets. The company's investigational pipeline includes small-molecule therapies aimed at specific cancer-related targets. Programs have included darovasertib, a protein kinase C inhibitor being studied in uveal melanoma, and IDE397, a MAT2A inhibitor being developed for tumors with particular genetic alterations.

Further Reading

Analyst Recommendations for IDEAYA Biosciences (NASDAQ:IDYA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in IDEAYA Biosciences Right Now?

Before you consider IDEAYA Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEAYA Biosciences wasn't on the list.

While IDEAYA Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines